$ARWR

Arrowhead Pharmaceuticals (ARWR) reported Phase 3 trial results for plozasiran, showing 79-81% triglyceride reductions vs. 27% for placebo. Pooled analysis indicated a 78% reduction in pancreatitis events, but absolute risk reduction was 4.1%. ARWR plans to submit a broader-label application by 2026. Plozasiran is FDA-approved for familial chylomicronemia syndrome. The company aims to expand its use to severe hypertriglyceridemia. Triglyceride reductions were consistent, with 91-93% of treated p

HC Wainwright & Co. maintained a 'Buy' rating for Arrowhead Pharmaceuticals (ARWR) with a $120.00 price target. The stock is currently trading at $82.39, which is 52.3% above its GF Value™ of $54.09. The company has a GF Score™ of 49/100, indicating moderate performance. Insiders have sold $1,186,600 worth of shares in the last three months. Arrowhead focuses on RNAi therapies for genetic diseases.

Plozasiran, an FDA-approved drug by Arrowhead, reduced triglycerides by up to 81% in severe hypertriglyceridemia patients and prevented pancreatitis. Two trials, SHASTA-3 and SHASTA-4, showed sustained reductions and favorable safety profiles. Gerald F. Watts, a cardiometabolic medicine professor, highlighted the therapy's potential impact on clinical practice. The drug is not yet approved for severe hypertriglyceridemia.

Arrowhead Pharmaceuticals presented late-stage trial results for plozasiran (Redemplo) in severe hypertriglyceridemia, showing favorable safety and efficacy. Analysts are divided: Stifel highlights its safety and dosing advantages over Ionis' Tryngolza, while BMO favors Tryngolza due to glycemic control concerns. Arrowhead plans an FDA submission for expanded use later this year.

Arrowhead Pharmaceuticals presented Phase 3 data showing plozasiran reduced triglycerides by 79-81% and acute pancreatitis events by 78% in severe hypertriglyceridemia patients. Over 90% of patients achieved TG levels below 500 mg/dL. The company plans to file an FDA application by year-end 2026, utilizing a Priority Review Voucher. Plozasiran demonstrated a favorable safety profile.

OLUKOTUN ADEOYE Y sold 2,000 shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $86.96 ($0.17M total) on 2026-08-18.

PERRY MICHAEL S sold 11,600 shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $87.30 ($1.01M total) on 2026-08-18.

Arrowhead Pharmaceuticals (ARWR) gained attention after its plozasiran therapy was listed in the Lauer-Taxe database following European marketing authorization. The company's stock has seen significant gains, with a 30-day return of 24.79% and a year-to-date return of 31.89%. Analysts debate its valuation, with some arguing it is undervalued at $89.41, while others point to its high P/S multiple and ongoing losses.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.

Arrowhead Pharmaceuticals (ARWR) disclosed that Avoro Capital Advisors LLC and controlling person Behzad Aghazadeh beneficially own 13,823,383 shares, including 2,467,828 shares issuable on warrant exercise. Using 140,857,021 shares outstanding as of May 1, 2026, the stake equals 9.64% assuming warrants are exercised.